Table 1.
Total accrual by Disease to NCI-MATCH.
| Screening Cohort N = 6390 |
Outside Assay N = 762 |
|
|---|---|---|
| Colorectal Cancer | 963 (15.1%) | 76 (10%) |
| Breast | 764 (12%) | 85 (11.2%) |
| Ovarian | 610 (9.5%) | 38 (5.0%) |
| NSCLC | 485 (7.6%) | 53 (7.0%) |
| Pancreas | 413 (6.5%) | 25 (3.3%) |
| Uterine Cancer | 402 (6.3%) | 70 (9.2%) |
| Liver and Hepatobiliary Cancer | 290 (4.5%) | 39 (5.1%) |
| Sarcoma | 288 (4.5%) | 29 (3.8%) |
| Head and Neck | 239 (3.7%) | 34 (4.5%) |
| Neuroendocrine Cancer | 214 (3.3%) | 11 (1.4%) |
| Gastroesophageal Cancer | 211 (3.3%) | 34 (4.5%) |
| Prostate Cancer | 157 (2.5%) | 33 (4.3%) |
| Bladder/Urothelial | 108 (1.7%) | 17 (2.2%) |
| Cervical Cancer | 103 (1.6%) | 9 (1.2%) |
| CNS | 103 (1.6%) | 106 (13.9%) |
| Small Cell Lung Cancer | 90 (1.4%) | 4 (0.5%) |
| Melanoma | 85 (1.3%) | 14 (1.8%) |
| Kidney | 83 (1.3%) | 12 (1.6%) |
| Lymphoma | 55 (0.9%) | 1 (0.1%) |
| Mesothelioma | 55 (0.9%) | 2 (0.3%) |
| Anal Cancer | 52 (0.8%) | 6 (0.8%) |
| Myeloma | 1 (<0.1%) | 1 (0.1%) |
| Other | 619 (9.7%) | 63 (8.3%) |